Financial Wire

Swiss Market Index Recovers; Sika, PolyPeptide Group Shares Jump

-- The blue-chip Swiss Market Index bounced back on Tuesday, closing 0.94% higher, as investors digest the latest economy-related and corporate releases while keeping an eye on geopolitical developments.

On the macroeconomic front, the International Monetary Fund lowered its 2026 global growth forecast to 3.1% in its April World Economic Outlook report, down by 0.2 percentage point from its previous estimate, under the assumption that the ongoing conflict in the Middle East remains limited in duration and scope. For 2027, the global growth is still expected to stand at 3.2%.

For the euro area, the economic growth projections for 2026 and 2027 were both trimmed by 0.2 pp to 1.1% and 1.2%, respectively, while the estimates for the UK were cut by 0.5 pp and 0.2 pp to 0.8% and 1.3%.

Back home, Swiss President Guy Parmelin and Federal Councilor Karin Keller-Sutter are set to attend the 2026 IMF and World Bank Spring Meetings and G20 finance ministers meeting in the US this week, according to Switzerland's Federal Council. Swiss National Bank (SNBN.SW) Governing Board Chairman Martin Schlegel will also be part of the delegation.

"The Spring Meetings will focus on global economic and development policy challenges. In the current environment of geopolitical conflicts and trade tensions, it is particularly important for Switzerland to advocate reliable economic relations and open markets in multilateral bodies and bilateral contacts. Healthy public finances, price stability and a robust global monetary and financial system are also crucial for a resilient economy and lasting prosperity," the government said.

Over to corporates, Sika (SIKA.SW) reported a 7% year-over-year drop in first-quarter net sales to 2.49 billion francs. The result was dented by a foreign currency impact of 213 million francs, which the Swiss specialty chemicals group mainly attributed to the franc's strength against Asian currencies and the US dollar. For full-year 2026, the company reaffirmed its sales growth guidance of between 1% and 4% in local currencies. The stock gained 7.94% at closing.

PolyPeptide Group (PPGN.SW) also saw its shares rise 4.46% after disclosing that it is at an early stage of reviewing potential strategic options to further improve its long-term value for shareholders. Amid market chatter that it drew takeover interest from certain investors, the Swiss contract development and manufacturing organization noted that it has yet to decide on the review.

相关文章

Asia

Emerald Resources在3月份季度推进了西澳大利亚和柬埔寨的项目。

根据周二提交给澳大利亚证券交易所的文件,Emerald Resources(ASX:EMR)表示,截至3月31日的季度,该公司在西澳大利亚的丁戈岭金矿项目、梅莫特金矿项目、奥克瓦金矿以及柬埔寨的勘探权地均发现了金矿化。 丁戈岭金矿项目的钻探结果显示,在619米深处钻遇了45米厚的矿层,金品位为4.1克/吨;其中包括在641米深处钻遇的18.5米厚的矿层,金品位为5.2克/吨。 该公司表示,自1月份矿产资源估算以来,丁戈岭金矿项目的勘探工作主要集中在露天矿坑的延伸和地下开采潜力两方面。 文件还补充道,梅莫特金矿项目的钻探结果显示,在40米深处钻遇了2米厚的矿层,金品位为50.3克/吨;在1米深处钻遇了14米厚的矿层,金品位为3.4克/吨。 奥克瓦乌金矿的矿脉交汇点在 347 米处达到 3 米厚,金品位为每吨 59 克;在 448 米处达到 22 米厚,金品位为每吨 1.9 克。

$ASX:EMR
Asia

澳大利亚临床实验室否认维多利亚州最高法院提起的集体诉讼中的指控

据澳大利亚证券交易所周二提交的文件显示,澳大利亚临床实验室(ASX:ACL)否认了米歇尔·拉布-伊万诺夫(Michelle Raab-Ivanov)在维多利亚州最高法院提起的代表诉讼中的指控,并计划“全力”应诉。 文件称,该诉讼代表的是2022年7月15日之前曾是该公司和/或其子公司Medlab Pathology的客户,且其个人信息在2022年2月Medlab Pathology遭受网络攻击后受到影响的个人。 根据文件,该诉讼旨在根据涉嫌违反澳大利亚消费者法的行为,为受影响的个人寻求损害赔偿。

$ASX:ACL
Asia

Challenger 将赎回所有未偿还的 Challenger Capital 票据 3

根据周二提交给澳大利亚证券交易所的文件,Challenger(ASX:CGF)将于5月25日以每张100澳元的面值现金赎回所有未偿还的Challenger Capital Notes 3。 此次赎回已获得澳大利亚审慎监管局(APRA)的批准。 该公司表示,预计将于5月25日向所有截至5月15日登记在册的持有人支付每张票据1.47澳元的最终分配款。

$ASX:CGF